ANIP (ANI Pharmaceuticals) Insider Ownership: 11.91 % (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIP ANI Pharmaceuticals Inc ANIP
80 GF Score
Price $78.45
GF Value $101.57
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ANI Pharmaceuticals Insider Ownership?

ANI Pharmaceuticals ANIP -5.35% 80 Insider Ownership is 11.91 % as of Aug. 08, 2026. GuruFocus rates ANIP with a GF Score™ of 80/100 and a GF Value™ of $101.57 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ANI Pharmaceuticals's insider ownership is 11.91%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ANI Pharmaceuticals's Institutional Ownership is 103.56%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ANI Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 81.96%.

ANI Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for ANI Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANI Pharmaceuticals Insider Ownership Chart

ANI Pharmaceuticals Historical Data

The historical data trend for ANI Pharmaceuticals can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 13.65 13.01 12.61 12.61 12.46 12.44 11.90 11.86 11.93 11.91
ANIP
80GF Score
ANI Pharmaceuticals Inc ANIP
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ANI Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 11.91 % mean?
ANI Pharmaceuticals (ANIP) has a Insider Ownership of 11.91 % as of Aug. 08, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on ANI Pharmaceuticals and its competitors.
Is ANI Pharmaceuticals' Insider Ownership too high?
ANI Pharmaceuticals' current Insider Ownership is 11.91 %. Overall, ANI Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Insider Ownership compare to TRLV and AMLX?
ANI Pharmaceuticals' Insider Ownership of 11.91 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on ANI Pharmaceuticals and its competitors. ANI Pharmaceuticals's current Insider Ownership is 11.91 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (ANIP) is currently considered Modestly Undervalued. The stock's GF Value™ is $101.57, compared to a current price of $78.45 — trading 22.8% below its estimated fair value. The current Insider Ownership is 11.91 %. ANI Pharmaceuticals' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For ANI Pharmaceuticals (ANIP), the current Insider Ownership is 11.91 % as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ANI Pharmaceuticals (ANIP) Overvalued in 2026?

Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued. The current stock price of $78.45 is trading 22.8% below its estimated GF Value™ of $101.57. GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for ANIP:

  • Insider Ownership: 11.91 %
  • GF Value™: $101.57 vs. price of $78.45 (22.8% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the ANIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANI Pharmaceuticals Business Description

Other Exchanges BSFA:Germany
Address 210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
80GF Score

Get the complete analysis for ANIP

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$78.45
Price
$101.57
GF Value